Iniciar sesión Regístrese gratis

Beam Therapeutics Ingresos

¿Qué es el Ingresos de Beam Therapeutics?

El Ingresos de Beam Therapeutics Inc. es -$143.01

¿Cuál es la definición de Ingresos?

El ingreso neto disponible para los accionistas comunes es igual al ingreso neto menos los dividendos preferentes pagados.

Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.

Ingresos de compañías en Sector Health Care en NASDAQ en comparadas con Beam Therapeutics

¿Qué hace Beam Therapeutics?

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Empresas con ingresos similar a Beam Therapeutics